



Corporate Press Release
Tuesday, August 10, 2021

The University of Oxford's head of innovation and leading translational research expert Chas Bountra, PhD elected Non-Executive Director of Kyttaro

Dr. Bountra's appointment will support Kyttaro's goal of accelerating translation research to address high unmet medical needs and improve patients' lives

LONDON, August 10, 2021 – Kyttaro Limited announced the appointment of Chas Bountra, PhD, as Non-Executive Director. As a Principal Investigator, entrepreneur, and former pharmaceutical industry executive, Dr. Bountra brings highly relevant and extensive experience in bioscience, translational research, and drug development to the Kyttaro organization.

Dr. Bountra is the Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford. He is also the Director of the Centre for Medicines Discovery in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology. Between 2008 and 2020, Dr. Bountra was Director of the Structural Genomics Consortium Oxford where he established a leading research group in human protein structural biology and a highly successful open innovation public-private partnership. Before joining Oxford in 2008, Dr. Bountra worked for GlaxoSmithKline as Vice President and Head of Biology, where he was involved in the identification of over 40 clinical candidates for many gastro-intestinal, inflammatory, and neuro-psychiatric diseases. He also provides expert advice to academic, biotech, and pharma drug discovery programs as well as government and charitable research funding bodies.

Dr. Bountra is joining the Board which includes founding Non-Executive Director and shareholder William Stovin, who is also the President and Director of Markel International, and Kyttaro Founder and CEO Douglas Eby.



Douglas Eby, CEO of Kyttaro and Cambridge Science, commented: *“I had the distinct pleasure of meeting and getting to know Chas through our involvement at Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, where he serves as an Advisory Board Member and I as a Senior Fellow. Chas is a translational research visionary, someone who cares deeply about accelerating life sciences innovation, and a person who is thinking in transformational terms. I am looking forward to working with him and to accomplishing something important in the biotechnology industry.”*

Dr. Chas Bountra, New Non-Executive Director of Kyttaro, stated: *“I am very excited to join the team at Kyttaro who aims to accelerate translational research using an innovative approach in order to address unmet needs and help patients. Society is increasingly desperate for innovative medicines, and I believe we need to apply new approaches that can effectively translate academic research and discover novel patient relevant drug solutions.”*

Dr. Alan Ashworth, Scientific Advisory Board Chair, former CEO of the Institute of Cancer Research and current President of the UCSF Helen Diller Family Comprehensive Cancer Center, expressed his strong support for the appointment: *“Dr. Bountra is a world-renowned translational research expert who works at one of the leading UK and global universities and I am pleased to have him join Kyttaro as Non-Executive Director. His experience, reputation, and network will certainly benefit Kyttaro in achieving our goal of identifying and translating UK biotech opportunities into novel pharmacological therapies.”*



ABOUT KYTTARO

Launched in Q2 2021, Kyttaro Ltd is a pure-play biotech company based in London, UK. Kyttaro aims to partner with pharma companies to develop clinical-stage assets and invest in novel biotech intellectual property (IP) developed in premier UK research institutions. Licensing clinical stage pharma assets will provide Kyttaro with a quick route to market and the opportunity to leverage pharma experience for in-house research and development. In parallel, Kyttaro aims to address the translational funding gap and acquire high quality academic biotech IP that can be advanced into the clinic through our own research within several years. The company's capital allocation approach prioritizes three key criteria: People, Science, and Intellectual Property. The Kyttaro team is sourcing, analyzing, and conducting diligence on biotech opportunities that address high unmet medical needs across key disease areas such as oncology, metabolic, cardiovascular, gastro-intestinal, and respiratory disease with the ultimate goal of improving patients' lives.

ABOUT CAMBRIDGE SCIENCE

Cambridge Science (CSC), which launched in 2018, is based in Kendall Square in Cambridge, Massachusetts. CSC is a new breed bioscience company with a mission to improve patient lives through the acceleration of translational research and creating long-term value for our shareholders. The CSC team launches, finances, and manages biotech companies commercializing novel technologies developed in the top labs at the world's premier research institutions. Apart from Kyttaro, CSC has already launched three emerging life science companies, Vivtex, Ovibio, and Kodika, and will continue to evolve into a diversified biotech company running multiple research and development, clinical, and commercial programs. Through pursuing the venture creation business model, CSC has been able to leverage its top-tier science and network across scientific programs to create a differentiated value proposition for its stakeholders. With the launch of Kyttaro, CSC is looking to repeat its early success in the US market by deploying some of the same competitive advantages to the UK biotech market.

ABOUT UK BIOTECH MARKET

The UK is world-leading in terms of medical research and is home to four of the top ten medical research universities globally but has yet to reach its full business potential of translating the technology into startups and the ultimate commercialization into solutions for patients. Compared to its US counterpart, the translational research market in the UK is characterized by reduced competition, more attractive valuations, and a larger funding gap for early-stage medical research and development. Given the world-class quality of the science, this is an unsustainable market dynamic and ripe for change by organizations such as Kyttaro and CSC. Recent data suggests though that the UK marketplace is changing due to increasing demand from global investors which resulted in c.£2.4B biotech / life-science investments in the first half of 2021 (compared to £2.8B in the whole of 2020 which itself was a record year). Additional momentum for the UK market is created by new UK government funding initiatives such as the Life-Science Investment Program.

For more information, contact: Matthias Thurner, DPhil (VP of Scientific Strategy): mthurner@kyttaro.com